软肝汤联合阿德福韦酯治疗代偿期乙肝肝硬化42例

Treating 42 Cases of Hepatitis B Cirrhosis at Compensatory Phase by Liver-softening Decoction Combined with Adefovir Dipivoxil

目的:观察软肝汤联合阿德福韦治疗代偿期乙肝肝硬化的临床疗效及安全性。方法:将85例患者随机分为观察组42例、对照组43例,对照组给予阿德福韦酯治疗,观察组在对照组基础上给予软肝汤治疗。2组均连续治疗12周。观察2组临床疗效及治疗前后肝功能及肝纤维化指标、脾脏厚度的变化情况。结果:总有效率观察组为78.6%,对照组为58.1%,2组比较差异有统计学意义(P<0.05)。肝功能及肝纤维化指标治疗前后2组组内比较,差异有统计学意义(P<0.05);治疗后2组组间比较,差异有统计学意义(P<0.05)。脾脏厚度治疗前后2组组内比较,差异有统计学意义(P<0.05);治疗后2组组间比较,差异有统计学意义(P<0.05)。不良反应发生率2组比较,差异无统计学意义(P>0.05)。结论:软肝汤联合阿德福韦酯治疗代偿期乙肝肝硬化疗效显著,安全性好。

Objective: To investigated clinical effects of liver-softening decoction jointed with adefovir dipivoxil in treating hepatitis B cirrhosis at compensatory phase and its safety. Methods: All 85 patients were randomly separated into 42 cases of the observation group and 43 cases of the control group, the patients in the control group were treated by adefovir dipivoxil, and the ones in the observation group were given liver-softening decoction based on adefovir dipivoxil. Both groups were treated for 12 weeks consecutively. Clinical effects, liver function, hepatic fibrosis indexes and spleen thickness before and after treating of both groups were observed. Results: Total effective rate of the observation group was 78.6%, higher than 58.1% of the control group, the difference had statistical meaning(P<0.05). The difference was statistically significant in the comparisons of liver function and hepatic fibrosis indexes before and after treating within two groups(P<0.05); there was a significant difference in the comparisons between both groups after treating(P<0.05). When spleen thickness of both groups were compared before and after treating within the group, and the difference had statistical meaning(P<0.05); there was a significant difference in the comparisons between both groups after treating(P<0.05). The difference had no statistical meaning in the comparisons of the incidence of adverse reaction between both groups(P>0.05). Conclusion: Liver-softening decoction jointed with adefovir dipivoxil could obtain notable effects in treating hepatitis B cirrhosis at compensatory phase with the high safety.